Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR-mutation”

1,003 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 1,003 results

Early research (Phase 1)UnknownNCT04448379
What this trial is testing

Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer

Who this might be right for
Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Shanghai JMT-Bio Inc. 48
Early research (Phase 1)Ended earlyNCT03246854
What this trial is testing

DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer

Who this might be right for
Head and Neck CancerNSCLC
National Health Research Institutes, Taiwan 6
Not applicableUnknownNCT04909073
What this trial is testing

Observational Study of Afatinib 30 mg Daily

Who this might be right for
Non-Small Cell Lung CancerEpidermal Growth Factor Receptor Mutation
National University Hospital, Singapore 69
Testing effectiveness (Phase 2)WithdrawnNCT02355431
What this trial is testing

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Who this might be right for
Solid Tumors and Hematologic MalignancyNSCLC (Non-small Cell Lung Carcinoma)
Incyte Corporation
Large-scale testing (Phase 3)UnknownNCT02387086
What this trial is testing

Gefitinib Combined With Thalidomide to Treat NSCLC

Who this might be right for
NSCLC
Bai Jun 380
Testing effectiveness (Phase 2)UnknownNCT02407366
What this trial is testing

Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
People's Hospital of Guangxi Zhuang Autonomous Region 80
Testing effectiveness (Phase 2)UnknownNCT01131429
What this trial is testing

A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations

Who this might be right for
Neoplasms, LungCarcinoma, Non-Small Cell LungDrug Therapy+1 more
Chinese PLA General Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT05536505
What this trial is testing

Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC

Who this might be right for
MRD
Guangdong Association of Clinical Trials 180
Testing effectiveness (Phase 2)UnknownNCT03647956
What this trial is testing

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Activating Mutation
The University of Hong Kong 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05751187
What this trial is testing

Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients

Who this might be right for
Non-squamous NSCLC
Shanghai Chest Hospital 54
Large-scale testing (Phase 3)Active Not RecruitingNCT04143607
What this trial is testing

ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC

Who this might be right for
Locally Advanced or Metastatic NSCLC
Jiangsu Aosaikang Pharmaceutical Co., Ltd. 337
Testing effectiveness (Phase 2)Study completedNCT00588445
What this trial is testing

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Who this might be right for
Lung CancerNon-small Cell Lung CancerBronchioloalveolar Cancer
Memorial Sloan Kettering Cancer Center 65
Testing effectiveness (Phase 2)Looking for participantsNCT07505173
What this trial is testing

Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer

Who this might be right for
Naive Advanced Non-small Cell Lung Cancer With EGFR-sensitive Mutations (EGFR Exon 19 Deletion and Exon 21 L858R Mutation) and Symptomatic Brain Metastases
Tianjin Medical University Cancer Institute and Hospital 74
Not applicableStudy completedNCT04236102
What this trial is testing

KEBI-Cyto Study - Use of the Biocartis Idylla

Who this might be right for
Pancreatic AdenocarcinomaLung Cancer
Royal Cornwall Hospitals Trust 55
Testing effectiveness (Phase 2)UnknownNCT05338619
What this trial is testing

Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy

Who this might be right for
Non-small Cell Lung Cancer Stage IIIEGFR Positive Non-small Cell Lung CancerNon-squamous Non-small-cell Lung Cancer
Sung Yong Lee 77
Testing effectiveness (Phase 2)Study completedNCT02716311
What this trial is testing

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Intergroupe Francophone de Cancerologie Thoracique 118
Testing effectiveness (Phase 2)Active Not RecruitingNCT03778229
What this trial is testing

Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib

Who this might be right for
Carcinoma
AstraZeneca 367
Not applicableUnknownNCT01838577
What this trial is testing

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

Who this might be right for
EGFR Mutation Positive Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 2,000
Early research (Phase 1)Looking for participantsNCT06186401
What this trial is testing

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Who this might be right for
EGFR Gene MutationGlioblastomaMGMT-Unmethylated Glioblastoma+1 more
Hideho Okada, MD, PhD 20
Large-scale testing (Phase 3)Study completedNCT02959749
What this trial is testing

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Who this might be right for
Progression Free Survival
Qingdao Central Hospital 147
Next Page